For most of the 1960s, the sedative thalidomide was sold widely across Europe, where it caused a generation of children to be born with severe limb deformities. In the United States, the drug's story is usually told as one of prevention — a tale of a single federal scientist's stubborn refusal to let it reach American pharmacy shelves. But that version, survivors and advocates say, leaves out a large chapter: thousands of American women were given the drug anyway, without approval and without being told what it was.
"When Cincinnati-based pharmaceutical company William S. Merrell applied for Food and Drug Administration approval for a German-made sedative in late 1960, executives expected the application to move quickly and to be on store shelves in time for Christmas," the NPR report details. The drug was not approved that year, or the next. The delay, and everything that followed, came down largely to one persistent medical reviewer.
Dr. Frances Oldham Kelsey, a pharmacologist then working at the FDA, dug into the drug's data and raised concerns that the evidence submitted was inadequate to support marketing the drug in the United States. Kelsey was subsequently credited with blocking general approval, and President John F. Kennedy publicly praised her for sparing the country a tragedy of the kind that had struck families in Germany. A widely circulated photograph from Oct. 15, 1962, shows Kelsey holding three packages of Contergan, the German brand name for thalidomide.
Kelsey's actions are widely described as a turning point in American drug regulation. By demanding better safety evidence and by insisting on responsible testing, she helped set in motion a tougher, more systematic approval process — the framework of requirements that still governs how drugs reach patients today.
But the point of regulation is to prevent harm, not merely to make paperwork. And here, according to the adults who were exposed to thalidomide in utero, the paperwork and the practice diverged.
Doctors were already dispensing thalidomide to thousands of patients in the United States, including pregnant women, at a time when the drug had never been approved for general use. Some of the women who took it gave birth to children with severely deformed limbs. Those children are now adults, and many of them say their medical histories were never properly recorded, their diagnoses never officially linked to the drug, and their existence never formally acknowledged by the country where it happened to them.
"We go to doctors today who say it didn't happen here in the United States. Oh yeah, it did," Gwen Riechmann, who was born with phocomelia, told The Ohio Newsroom, in coverage linked from the NPR report. Phocomelia is the signature shortened-limb deformity associated with thalidomide exposure during pregnancy. Riechmann's mother, pregnant in the early 1960s, was given a new sedative by her doctor — part of a period when the drug was circulating in American clinics without the approval process designed to catch exactly this scenario.
The condition itself is rare, but Riechmann and others note that the discrepancy is not about biology. Phocomelia is somewhat more common outside the United States, in countries such as Britain and Germany, where thalidomide had been approved and marketed on a wide scale. Any difference in incidence, survivors argue, tracks availability rather than chance.
That gap between documented and lived experience is what drives the current push. Survivor advocates want the federal government to formally acknowledge that thalidomide exposure happened in the United States in meaningful numbers, and that the resulting injuries occurred outside of any trial the government approved or tracked.
Legal history complicates the accounting. American families who sued over thalidomide-related harms in the 1960s and 1970s generally resolved their claims through settlements in which the companies did not admit liability — leaving a paper record of compensation payments but little in the way of official acknowledgment of fault or of the scale of exposure.
Health historians and patient advocates point to a structural reason for the undercount: drug regulation governs the market, not necessarily the clinic. Physicians may use an investigational drug, or prescribe a drug for an unapproved indication, with paperwork that never reaches a federal record. When that happens, the exposure still happens — and the children still arrive — but the numbers never enter the count the government publishes.
For survivors, the consequences of an incomplete record are practical, not merely symbolic. Without documented exposure, a patient can struggle to have a decades-old birth deformity formally connected to a drug; without recognition, a cohort can be left without the acknowledgment that many national birth-defect cohorts receive, including survivor registries, research priorities and formal apologies.
Merrell's Cincinnati operations, where the company's application for thalidomide sat before the FDA, have become a focal point for local reporting on survivor recognition. The Ohio Newsroom's account of survivors in the Cincinnati area frames the issue as both a personal and a regional reckoning.
The current generation of adult survivors is asking a narrow question with wide implications: How many Americans were exposed, and who will say so officially?
As Kelsey recognized more than six decades ago, the gap between a drug's theoretical safety record and its actual use is where catastrophe hides. The survivors now pressing for acknowledgment are making a related point — that the public record of a drug's harm is only as complete as the paperwork behind it, and that the absence of a count is not the same thing as the absence of harm.
(0)